For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Edwards Lifesciences CorporationEW US · Health Care · USD Current price$103.88as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 5Buy 20Hold 4Strong Sell 127 analysts 3-year price (USD)Factor profileMulti-factor score 96 / 100 Market data
Business descriptionEdwards Lifesciences is a global leader in medical innovations for structural heart disease, operating across Transcatheter Aortic Valve Replacement (TAVR, 74% of 2025 sales), Transcatheter Mitral and Tricuspid Therapies (TMTT, 9%), and Surgical Structural Heart (17%). Following the 2024 spinoff of its Critical Care unit to BD, EW is now a pure-play structural heart company with a dominant position in minimally invasive heart valve replacement. Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $103.88 · Nov 20, 2026· USD
CFRA Ratingbuy
TBI Multi Score96
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: EWBusiness description
Edwards Lifesciences is a global leader in medical innovations for structural heart disease, operating across Transcatheter Aortic Valve Replacement (TAVR, 74% of 2025 sales), Transcatheter Mitral and Tricuspid Therapies (TMTT, 9%), and Surgical Structural Heart (17%). Following the 2024 spinoff of its Critical Care unit to BD, EW is now a pure-play structural heart company with a dominant position in minimally invasive heart valve replacement.
Competitive moat
- First-mover and technology leader in TAVR with the Edwards SAPIEN valve family, a market it pioneered and has dominated since 2007 (Europe) and 2011 (U.S.).
- Only company with approved tricuspid valve replacement (Evoque), creating a first-mover advantage in a nascent $2B+ TMTT market by 2030.
- Substantial R&D investment (17.8% of 2024 revenues) sustaining a pipeline of next-generation structural heart innovations.
- Negative net debt and conservative 6% debt/capital structure providing significant strategic flexibility.
- Strong clinical data (EARLY TAVR study) driving earlier disease intervention and expanding the addressable patient population.
Recent developments
- TMTT growth accelerating: EW expects TMTT sales to reach at least $2B by 2030 (from $551M in 2025), fueled by SAPIEN M3 U.S. approval and Evoque tricuspid system.
- Q1 2026 beat and guidance raise: Full-year 2026 guidance raised to 10% constant currency sales growth (from 9%) and adjusted EPS midpoint of $3.00 (+17% Y/Y).
- EARLY TAVR data driving volumes: Clinical evidence supporting earlier aortic stenosis intervention expanding the patient pool.
- FTC blocked JenaValve acquisition (2025): Deal terminated in early 2026; may support better near-term margins by avoiding acquisition-related costs.
Investment risks / red flags
- TAVR competition: Intense competition from Medtronic and Abbott in the core TAVR market could pressure market share or pricing.
- Elective procedure disruptions: Macroeconomic shocks or staffing shortages could delay TAVR/TMTT procedure volumes.
- FTC/regulatory risk: FTC blocking of the JenaValve deal signals heightened antitrust scrutiny on structural heart M&A.
- Valuation premium: P/E of 28.6x on 2026 EPS reflects growth expectations that may be vulnerable to any TAVR/TMTT adoption slowdown.
Market Data
Source: mkts.io · Nov 20, 2026, 04:01 UTC
Key Metrics
P/E (TTM)60.40
P/E (Fwd)30.68
Dividend0.00%
Beta0.83
52W High$108.00
52W Low$74.66
Analyst Consensus
5
20
4
Strong Buy5Buy20Hold4Strong Sell127 analysts
Consensus Target$113.68
+9.4% upside
Calendar Events
Next EarningsNov 4, 2026
Financials
Revenue$6.67B
Rev Growth10.50%
Earnings Growth6.70%
Gross Margin78.02%
Op Margin28.82%
Profit Margin15.30%
EBITDA$2.09B
ROA8.77%
ROE9.33%
Rev/Share$11.54
Total Cash$4.64B
Total Debt$704.50M
D/E Ratio6.43
Free Cash Flow$1.15B
Op Cash Flow$1.72B
Current Ratio4.60
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 0.66 | $1.71B |
| +1q | 0.84 | $1.80B |
| 0y | 3.01 | $6.81B |
| +1y | 3.39 | $7.48B |
Earnings
Quarterly EPS
4Q2025
Est: 0.620.58Miss
1Q2026
Est: 0.730.78Beat
2Q2026
Est: 0.740.78Beat
3Q2026
Est: 0.740.80Beat
Annual
2022
Rev $5.38BEarn $1.52B
2023
Rev $6.00BEarn $1.40B
2024
Rev $5.44BEarn $4.17B
2025
Rev $6.07BEarn $1.07B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 11, 2026 | TD Cowen | main | Buy |
| Nov 6, 2026 | UBS | main | Buy |
| Nov 5, 2026 | JP Morgan | main | Overweight |
| Nov 5, 2026 | Citigroup | main | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform |
| Nov 5, 2026 | RBC Capital | main | Outperform |
